Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early prophylactic CD4+ donor lymphocyte infusion after T-cell depleted allogeneic stem cell transplantation
NL-OMON30913Phase 2Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2007
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD4+ donor lymphocytes in leukemia, myelodysplastic syndrome (MDS), multiple myeloma (MM) and 1 more, sponsored by Leiden University Medical Center. Primary endpoint: Immunological recovery with acceptable GVHD incidence. Planned start Oct 2007; status: not yet recruiting.
02
Drugs
CD4+ donor lymphocytes
03
Conditions
leukemiamyelodysplastic syndrome (MDS)multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NL-OMON30913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30913.